Cure My Disease

Don't miss your cure!

 Log in / Sign up

Five new weapons in the fight against painful skin disease

NCT ID NCT03827798

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing five different new drugs to see if they can help people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It involved 248 participants who received either one of the drugs or a placebo for 16 weeks. The main goal was to see if the drugs safely reduce the number of painful abscesses and nodules by at least 50%.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Advanced Medical Research

    Sandy Springs, Georgia, 30328, United States

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana, 46256, United States

  • Medical University of South Carolina MUSC

    Charleston, South Carolina, 29425, United States

  • NorthShore University Health System

    Evanston, Illinois, 60201, United States

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Brussels, 1070, Belgium

  • Novartis Investigative Site

    Prague, Prague 1, 11000, Czechia

  • Novartis Investigative Site

    Copenhagen, 2400, Denmark

  • Novartis Investigative Site

    Roskilde, 4000, Denmark

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Lyon, 69003, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Nice, 06202, France

  • Novartis Investigative Site

    Reims, 51100, France

  • Novartis Investigative Site

    Rouen, 76031, France

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Frankfurt, 60590, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Schwerin, 19055, Germany

  • Novartis Investigative Site

    Pécs, Baranya, 7623, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Szeged, H 6725, Hungary

  • Novartis Investigative Site

    Kopavogur, 201, Iceland

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    Groningen, 9713 GZ, Netherlands

  • Novartis Investigative Site

    Granada, Andalusia, 18014, Spain

  • Novartis Investigative Site

    Sabadell, Barcelona, 08208, Spain

  • Novartis Investigative Site

    Manises, Valencia, 46940, Spain

  • Novartis Investigative Site

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    Las Palmas GC, 35010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Olympian Clinical Research

    Clearwater, Florida, 33609, United States

  • Park Avenue Dermatology PA

    Orange Park, Florida, 32073, United States

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania, 17033-0850, United States

  • University Of South Florida

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA